GTx Inc. (NASDAQ:GTXI) major shareholder Peak Foundation Pyramid purchased 7,716,049 shares of the stock in a transaction that occurred on Friday, October 14th. The stock was acquired at an average cost of $0.81 per share, with a total value of $6,249,999.69. Following the acquisition, the insider now owns 38,249,528 shares in the company, valued at approximately $30,982,117.68. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Shares of GTx Inc. (NASDAQ:GTXI) opened at 0.9289 on Tuesday. GTx Inc. has a 52-week low of $0.29 and a 52-week high of $1.14. The company has a 50-day moving average of $0.75 and a 200-day moving average of $0.66. The stock has a market capitalization of $131.82 million, a price-to-earnings ratio of 5.5958 and a beta of 2.35.

GTx (NASDAQ:GTXI) last released its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.01. Equities research analysts anticipate that GTx Inc. will post ($0.12) EPS for the current year.

Insider Buying and Selling by Quarter for GTx (NASDAQ:GTXI)

GTXI has been the topic of a number of recent analyst reports. Jefferies Group reissued a “hold” rating and issued a $1.00 price objective on shares of GTx in a research report on Friday, September 9th. Zacks Investment Research raised shares of GTx from a “sell” rating to a “hold” rating in a research report on Tuesday, July 12th.

A hedge fund recently raised its stake in GTx stock. BVF Inc. IL increased its position in GTx Inc. (NASDAQ:GTXI) by 3.1% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 11,512,000 shares of the biopharmaceutical company’s stock after buying an additional 348,864 shares during the period. GTx comprises approximately 1.4% of BVF Inc. IL’s holdings, making the stock its 21st largest position. BVF Inc. IL owned 8.12% of GTx worth $5,756,000 as of its most recent SEC filing. Institutional investors own 10.78% of the company’s stock.

About GTx

GTx, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs).

5 Day Chart for NASDAQ:GTXI

Receive News & Ratings for GTx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTx Inc. and related companies with's FREE daily email newsletter.